<DOC>
	<DOCNO>NCT03068455</DOCNO>
	<brief_summary>The purpose study determine whether investigational immunotherapy Nivolumab , combine Ipilimumab , effective Nivolumab Ipilimumab , delay return cancer patient complete surgical removal stage IIIb/c/d stage IV Melanoma .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Nivolumab Combined With Ipilimumab Compared Nivolumab Ipilimumab Itself After Complete Surgical Removal Stage IIIb/c/d Stage IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Completely surgically resect stage IIIb/c/d stage IV melanoma within 12 week participation study . Must full activity , limited , must able walk carry activity light house work office work No prior anticancer treatment melanoma ( except surgery melanoma lesion ( ) and/or except adjuvant radiation therapy ( RT ) neurosurgical resection central nervous system ( CNS ) lesion ) History uveal melanoma Weight le equal 40 kg Patients active , know suspected autoimmune disease Prior treatment interferon ( complete &lt; 6 month prior participation study ) , antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathways Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>